Characteristics of humoral and cellular responses to coronavirus disease 2019 (COVID-19) inactivated vaccine in central China: A prospective, multicenter, longitudinal study

Introduction In China, the long-term immunogenicity and adverse effects of inactivated vaccines produced by different or the same manufacturer remain unclear. Therefore, the objective of this study was to evaluate the cellular immune responses and neutralizing antibody kinetics of homologous and heterologous administrations of an inactivated coronavirus disease 2019 (COVID-19) vaccine 240 days after the second vaccination. Methods This prospective, multicenter, observational, longitudinal study involved 595 participants with a negative SARS-CoV-2 polymerase chain reaction result who were serologically tested and followed for 8 months after vaccination. Neutralizing antibodies, interferon-gamma (IFN-γ), interleukin (IL)-6, CD4+ T-lymphocyte, and B-lymphocyte counts were evaluated in serum samples after stimulation with 2 μg/mL SARS-CoV-2 spike protein for 16 h at follow-up intervals of 2 months. Results Most participants [582/595; 146 male participants, 449 female participants; mean age 35 (26–50 years)] rapidly developed neutralizing antibodies after two doses of the vaccine administered 3-weeks apart. The positive rate of neutralizing antibodies peaked at 97.7% at 60–90 days, decreased, and stabilized at 82.9% at 181–240 days post-vaccination. Lower antibody concentrations were correlated with older age, longer duration after vaccination, non-health care workers, mixed-manufacturer vaccinations, and intervals of less than 40 days between two doses of vaccination, whereas lower IFN-γ levels and B-lymphocyte counts were associated with older age, blood type A, and non-health care workers. A higher IL-6 level was associated with older age, mixed-manufacturer vaccinations, intervals of less than 40 days between two doses of vaccination, and medical staff. Adverse reactions were mild or moderate and self-limited, with no serious events reported. Discussion Two doses of the Chinese inactivated vaccine induced robust and rapid antibody expression and cellular immune responses. Boosting vaccination is considered important, as antibodies and cellular immune responses were reduced in susceptible populations.

[1]  D. Parums Editorial: Rebound COVID-19 and Cessation of Antiviral Treatment for SARS-CoV-2 with Paxlovid and Molnupiravir , 2022, Medical science monitor : international medical journal of experimental and clinical research.

[2]  J. Domingo An updated review of the scientific literature on the origin of SARS-CoV-2 , 2022, Environmental Research.

[3]  J. Domingo What we know and what we need to know about the origin of SARS-CoV-2 , 2022, Environmental Research.

[4]  A. Pollard,et al.  Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial , 2022, The Lancet.

[5]  Y. Siaw,et al.  Intention to receive a COVID-19 vaccine booster dose and associated factors in Malaysia , 2022, Human vaccines & immunotherapeutics.

[6]  Wei Chen,et al.  Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial , 2022, The Lancet Respiratory Medicine.

[7]  Caijun Sun,et al.  Acceptance of COVID‐19 booster vaccination based on the protection motivation theory: A cross‐sectional study in China , 2022, Journal of medical virology.

[8]  Y. Lau,et al.  Safety and reactogenicity of a liquid formulation of human rotavirus vaccine (porcine circovirus-free): A phase III, observer-blind, randomized, multi-country study. , 2022, Vaccine.

[9]  M. Mni,et al.  Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections , 2022, Frontiers in Immunology.

[10]  H. Naruse,et al.  Antibody Responses to BNT162b2 Vaccination in Japan: Monitoring Vaccine Efficacy by Measuring IgG Antibodies against the Receptor-Binding Domain of SARS-CoV-2 , 2022, Microbiology spectrum.

[11]  G. Screaton,et al.  Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study , 2022, The Lancet.

[12]  U. V. Ukah,et al.  COVID-19 vaccine hesitancy in Africa: a scoping review , 2021, Global Health Research and Policy.

[13]  Yaolong Chen,et al.  COVID-19 vaccine guidelines was numerous in quantity but many lack transparent reporting of methodological practices , 2021, Journal of Clinical Epidemiology.

[14]  Wenhong Zhang,et al.  Recombinant protein subunit vaccine booster following two-dose inactivated vaccines dramatically enhanced anti-RBD responses and neutralizing titers against SARS-CoV-2 and Variants of Concern , 2021, Cell research.

[15]  M. Exline,et al.  Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity. , 2021, JAMA.

[16]  N. Gupta,et al.  Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses , 2021, The Lancet Infectious Diseases.

[17]  G. Gao Science-based COVID-19 vaccine development , 2021, National science review.

[18]  Denis Sauré,et al.  Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study , 2021, The Lancet Infectious Diseases.

[19]  Yihan Lu,et al.  COVID-19 vaccine coverage, concerns, and preferences among Chinese ICU clinicians: a nationwide online survey , 2021, Expert review of vaccines.

[20]  A. Huppert,et al.  BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers , 2021, The Lancet Respiratory Medicine.

[21]  A. Borobia,et al.  Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial , 2021, The Lancet.

[22]  A. Saven,et al.  ABO phenotype and clinical correlates of COVID-19 severity in hospitalized patients , 2021, Future science OA.

[23]  M. Davenport,et al.  Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19 , 2021, Nature communications.

[24]  D. Engeler,et al.  Prostatic Artery Embolisation Versus Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia: 2-yr Outcomes of a Randomised, Open-label, Single-centre Trial. , 2021, European urology.

[25]  Zigui Chen,et al.  Acceptance of the COVID-19 vaccine based on the health belief model: A population-based survey in Hong Kong , 2021, Vaccine.

[26]  Fulian Yin,et al.  Unfolding determinants of COVID-19 vaccine acceptance in China. , 2020, Journal of medical Internet research.

[27]  A. Shaw,et al.  First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. , 2020, The New England journal of medicine.

[28]  N. Tatonetti,et al.  Associations between blood type and COVID-19 infection, intubation, and death , 2020, Nature Communications.

[29]  T. Lam,et al.  Exposure to health misinformation about COVID-19 and increased tobacco and alcohol use: a population-based survey in Hong Kong , 2020, Tobacco Control.

[30]  Stephen H. Bell,et al.  A ?scoping review. , 2018, Sexual health.